Viking Therapeutics Inc
For the period ended Mar 31, 2024. Filed Apr 25, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed Apr 25, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information
Insider Adoption or Termination of Trading Arrangements:
During the fiscal quarter ended March 31, 2024, none of our directors or officers (as defined in Section 16 of the Securities Exchange Act of 1934, as amended) adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement,” as defined in Item 408(a) of Regulation S-K, except as described in the table below:
| Name & Title | Date Adopted | Type of Plan | Aggregate Number of Shares of Common Stock to be Sold Pursuant to Trading Arrangement | Duration |
|---|---|---|---|---|
| Greg Zante, Chief Financial Officer | February 2, 2024 | Rule 10b5-1 trading arrangement | 66,756 | August 1, 2024(1) |
| Marianne Mancini, Chief Operations Officer | February 1, 2024 | Rule 10b5-1 trading arrangement | 281,425 | April 20, 2025(1) |
The trading arrangement permits transactions through and including the earlier to occur of (a) the date that all shares subject to the trading arrangement have been sold and (b) the date listed in the table.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.